199 related articles for article (PubMed ID: 34932133)
1. The second-generation antipsychotic drug aripiprazole modulates the serotonergic system in pancreatic islets and induces beta cell dysfunction in female mice.
Grajales D; Vázquez P; Ruíz-Rosario M; Tudurí E; Mirasierra M; Ferreira V; Hitos AB; Koller D; Zubiaur P; Cigudosa JC; Abad-Santos F; Vallejo M; Quesada I; Tirosh B; Leibowitz G; Valverde ÁM
Diabetologia; 2022 Mar; 65(3):490-505. PubMed ID: 34932133
[TBL] [Abstract][Full Text] [Related]
2. Effects of the second-generation antipsychotic drugs aripiprazole and olanzapine on human adipocyte differentiation.
Vranic M; Ahmed F; Hetty S; Sarsenbayeva A; Ferreira V; Fanni G; Valverde ÁM; Eriksson JW; Pereira MJ
Mol Cell Endocrinol; 2023 Feb; 561():111828. PubMed ID: 36526026
[TBL] [Abstract][Full Text] [Related]
3. Metallothionein 1 negatively regulates glucose-stimulated insulin secretion and is differentially expressed in conditions of beta cell compensation and failure in mice and humans.
Bensellam M; Shi YC; Chan JY; Laybutt DR; Chae H; Abou-Samra M; Pappas EG; Thomas HE; Gilon P; Jonas JC
Diabetologia; 2019 Dec; 62(12):2273-2286. PubMed ID: 31624901
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons.
Kowalchuk C; Kanagasundaram P; Belsham DD; Hahn MK
Psychoneuroendocrinology; 2019 Jun; 104():42-48. PubMed ID: 30802709
[TBL] [Abstract][Full Text] [Related]
5. Reciprocal regulation of mTOR complexes in pancreatic islets from humans with type 2 diabetes.
Yuan T; Rafizadeh S; Gorrepati KD; Lupse B; Oberholzer J; Maedler K; Ardestani A
Diabetologia; 2017 Apr; 60(4):668-678. PubMed ID: 28004151
[TBL] [Abstract][Full Text] [Related]
6. Insulin resistance induced by olanzapine and other second-generation antipsychotics in Chinese patients with schizophrenia: a comparative review and meta-analysis.
Yu L; Wu S; Deng Y; Lei J; Yu L; Li W
Eur J Clin Pharmacol; 2019 Dec; 75(12):1621-1629. PubMed ID: 31428814
[TBL] [Abstract][Full Text] [Related]
7. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Rummel-Kluge C; Komossa K; Schwarz S; Hunger H; Schmid F; Lobos CA; Kissling W; Davis JM; Leucht S
Schizophr Res; 2010 Nov; 123(2-3):225-33. PubMed ID: 20692814
[TBL] [Abstract][Full Text] [Related]
8. Direct effects of antipsychotic drugs on insulin, energy sensing and inflammatory pathways in hypothalamic mouse neurons.
Kowalchuk C; Kanagasundaram P; McIntyre WB; Belsham DD; Hahn MK
Psychoneuroendocrinology; 2019 Nov; 109():104400. PubMed ID: 31404896
[TBL] [Abstract][Full Text] [Related]
9. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
Newcomer JW
CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
[TBL] [Abstract][Full Text] [Related]
10. Effects of second-generation antipsychotics on human subcutaneous adipose tissue metabolism.
Sarsenbayeva A; Marques-Santos CM; Thombare K; Di Nunzio G; Almby KE; Lundqvist M; Eriksson JW; Pereira MJ
Psychoneuroendocrinology; 2019 Dec; 110():104445. PubMed ID: 31563732
[TBL] [Abstract][Full Text] [Related]
11. Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies.
Bernardo M; Rico-Villademoros F; García-Rizo C; Rojo R; Gómez-Huelgas R
Adv Ther; 2021 May; 38(5):2491-2512. PubMed ID: 33826090
[TBL] [Abstract][Full Text] [Related]
12. Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor.
Weston-Green K; Huang XF; Deng C
CNS Drugs; 2013 Dec; 27(12):1069-80. PubMed ID: 24114586
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of Olanzapine-Induced Endoplasmic Reticulum Stress Improves Insulin Secretion in Pancreatic Beta Cells.
Grajales D; Vázquez P; Alén R; Hitos AB; Valverde ÁM
Metabolites; 2022 May; 12(5):. PubMed ID: 35629947
[TBL] [Abstract][Full Text] [Related]
14. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Mukundan A; Faulkner G; Cohn T; Remington G
Cochrane Database Syst Rev; 2010 Dec; (12):CD006629. PubMed ID: 21154372
[TBL] [Abstract][Full Text] [Related]
15. Second generation atypical antipsychotics olanzapine and aripiprazole reduce expression and secretion of inflammatory cytokines in human immune cells.
Stapel B; Sieve I; Falk CS; Bleich S; Hilfiker-Kleiner D; Kahl KG
J Psychiatr Res; 2018 Oct; 105():95-102. PubMed ID: 30216787
[TBL] [Abstract][Full Text] [Related]
16. The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine.
Chiu CC; Chen CH; Chen BY; Yu SH; Lu ML
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):866-70. PubMed ID: 20394794
[TBL] [Abstract][Full Text] [Related]
17. Glucose potentiates β-cell function by inducing
Zhang Y; Deng R; Yang X; Xu W; Liu Y; Li F; Zhang J; Tang H; Ji X; Bi Y; Wang X; Zhou L; Ning G
FASEB J; 2017 Dec; 31(12):5342-5355. PubMed ID: 28794173
[TBL] [Abstract][Full Text] [Related]
18. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
Lee SY; Park MH; Patkar AA; Pae CU
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):490-6. PubMed ID: 21146575
[TBL] [Abstract][Full Text] [Related]
19. The hepatokine fetuin-A disrupts functional maturation of pancreatic beta cells.
Gerst F; Kemter E; Lorza-Gil E; Kaiser G; Fritz AK; Nano R; Piemonti L; Gauder M; Dahl A; Nadalin S; Königsrainer A; Fend F; Birkenfeld AL; Wagner R; Heni M; Stefan N; Wolf E; Häring HU; Ullrich S
Diabetologia; 2021 Jun; 64(6):1358-1374. PubMed ID: 33765181
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial.
Nicol GE; Yingling MD; Flavin KS; Schweiger JA; Patterson BW; Schechtman KB; Newcomer JW
JAMA Psychiatry; 2018 Aug; 75(8):788-796. PubMed ID: 29898210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
